News Medical

Connect with over 100 specialists in mRNA process development

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...
BND

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...

mRNA Synthesis Raw Materials Market to Reach USD 2.67 Billion by 2032, Driven by Therapeutic Innovation – SNS Insider

Growing investments in mRNA vaccine and therapeutic platforms, along with regulatory acceleration, are fueling steady global demand for high-purity raw materials.Austin, Nov. 04, 2025 (GLOBE NEWSWIRE) ...
Nanowerk

New customizable nanomedicine platform shows promise for advancing personalized mRNA cancer therapeutics

A new mRNA platform targets tumors with precision, limits side effects, and converts immune-silent cancers into responsive ...
Nasdaq

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...
Charlotte Observer

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.